FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to endocrinology and cardiology and can be used in detection of early latent forms of carbohydrate metabolism inducing development of pancreatic diabetes. Blood serum sampled on an empty stomach is analysed for levels of glucose (G), triglycerides (TG) and concentration of apolipoproteins AI (apo AI) and AII (apo AII). The molar ratio apo AII/apo AI is calculated. The latent insulin resistance is detected by the molar ratio apo AII/apo AI>=0.35 with normal G and TG levels.
EFFECT: invention provides detecting the latent insulin resistance even in G and TG levels analysed on an empty stomach.
3 tbl, 1 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR EARLY HOSPITAL DETECTION OF INSULIN RESISTANCE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION | 2013 |
|
RU2549479C1 |
| METHOD OF SELECTING MEN AT PRE-DIABETES RISK GROUP AND TYPE 2 DIABETES MELLITUS | 2017 |
|
RU2695322C2 |
| METHOD FOR INSULIN RESISTANCE CORRECTION IN METABOLIC SYNDROME | 2009 |
|
RU2402326C1 |
| METHOD OF TREATING PATIENTS WITH METABOLIC SYNDROME | 2018 |
|
RU2699508C1 |
| METHOD FOR SCREENING DIAGNOSIS OF INSULIN RESISTANCE | 2012 |
|
RU2493566C1 |
| METHOD OF TREATING PATIENTS WITH METABOLIC SYNDROME | 2019 |
|
RU2706385C1 |
| METHOD FOR PREDICTING RISK OF DEVELOPMENT OF INSULIN RESISTANCE | 2019 |
|
RU2748034C2 |
| METHOD OF DIAGNOSING METABOLIC SYNDROME | 2010 |
|
RU2444298C1 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE ACCOMPANYING METABOLIC SYNDROME | 2018 |
|
RU2686042C1 |
| METHOD OF PERSONIFIED PREDICTION OF CLINICAL EFFECTIVENESS OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH METABOLIC SYNDROME | 2020 |
|
RU2737503C1 |
